Evaluation of adrenomedullin, growth differentiation factor-15, and atrial natriuretic peptide in patients with rheumatoid arthritis
DOI:
https://doi.org/10.15584/ejcem.2025.4.2Keywords:
adrenomedullin, angiotensinogen, growth differentiation factor-15, serum amyloid A-4 protein, rheumatoid arthritisAbstract
Introduction and aim. Rheumatoid arthritis (RA) is a chronic autoimmune disorder characterized by joint inflammation and systemic complications, including cardiovascular involvement. This study evaluated the diagnostic utility of angiotensinogen (AGT), serum amyloid A-4 protein (SAA4) and C-reactive protein (CRP) in RA, along with new cardiac biomarkers adrenomedullin (ADM), growth differentiation factor-15 (GDF-15), and atrial natriuretic peptide (ANP), to assess cardiac complications.
Material and methods. This case-control study included 61 RA patients (divided into newly diagnosed, sDMARD-treated, and sDMARD/bDMARD-treated groups) and 27 healthy controls. Serum levels of AGT, SAA4, CRP, ADM, GDF-15, and ANP were measured using ELISA. Statistical analyses were performed using SPSS software.
Results. RA patients exhibited significantly elevated levels of AGT (40.841±17.285 µg/mL), SAA4 (48.128±17.065 ng/mL), CRP (13.097±18.702 mg/L), ADM (96.295±19.424 pg/mL), GDF-15 (1247.049±854.335 pg/mL), and ANP (334.016±40.874 pg/mL) levels compared to controls (p≤0.001). No significant differences were observed between the treatment groups for AGT, SAA4, or CRP levels. Cardiac biomarkers (ADM, GDF-15, and ANP) remained elevated in all RA groups, with strong inter-parameter correlations (Spearman r>0.6).
Conclusion. AGT, SAA4, and CRP demonstrate robust diagnostic value for RA. Persistent elevation of ADM, GDF-15, and ANP in all patient groups confirms significant cardiac involvement in RA.
Downloads
References
Zielińska A, Tabarkiewicz J. Correlation between rheumatoid arthritis and periodontitis. Eur J Clin Exp Med. 2022;(4):451-458. doi: 10.15584/ejcem.2022.4.11
Rohit N, Thakur B, Jain A, Jain PK, Khare B, Jat YS. Comprehensive Review on Rheumatoid Arthritis. Int J Med Sci Pharma Res. 2022;8(3):39-45. doi: 10.22270/ijmspr.v8i3.58
Zhou J, Wang F, Qu Y, et al. Lesions of Bones and Joints Associated with Rheumatism. In: Radiology of Infectious and Inflammatory Diseases-Volume 5: Musculoskeletal System. Springer; 2022:285-332. doi: 10.1007/978-981-16-5003-1_9
Świtała A, Wyszyńska J, Czerwińska K, Dereń K, Podgórska-Bednarz J, Guzik A. Association between body mass and physical activity with quality of life in patients with rheumatoid arthritis. Eur J Clin Exp Med. 2017;(3):200-205. doi: 10.15584/ejcem.2017.3.3
Li XC, de Oliveira Leite AP, Chen X, et al. The intratubular and intracrine renin-angiotensin system in the proximal tubules of the kidney and its roles in angiotensin II-induced hypertension. In: Selected Chapters from the Renin-Angiotensin System. IntechOpen; 2019.
Ghafar MTA. An overview of the classical and tissue-derived renin-angiotensin-aldosterone system and its genetic polymorphisms in essential hypertension. Steroids. 2020;163:108701. doi: 10.1016/j.steroids.2020.108701
Cantero-Navarro E, Fernandez-Fernandez B, Ramos AM, et al. Renin-angiotensin system and inflammation update. Mol Cell Endocrinol. 2021;529:111254. doi: 10.1016/j.mce.2021.111254
Méndez-García LA, Escobedo G, Minguer-Uribe AG, et al. Role of the renin-angiotensin system in the development of COVID-19-associated neurological manifestations. Front Cell Neurosci. 2022;16:977039. doi: 10.3389/fncel.2022.977039
Abouelasrar Salama S, Gouwy M, Van Damme J, Struyf S. The turning away of serum amyloid A biological activities and receptor usage. Immunology. 2021;163(2):115-127. doi: 10.1111/imm.13295
Sunar I, Ataman Ş. Serum C-reactive protein/albumin ratio in rheumatoid arthritis and its relationship with disease activity, physical function, and quality of life. Arch Rheumatol. 2020;35(2):247. doi: 10.46497/ArchRheumatol.2020.7456
Sarzani R, Allevi M, Di Pentima C, Schiavi P, Spannella F, Giulietti F. Role of cardiac natriuretic peptides in heart structure and function. Int J Mol Sci. 2022;23(22):14415. doi: 10.3390/ijms232214415
Abassi Z, Khoury EE, Karram T, Aronson D. Edema formation in congestive heart failure and the underlying mechanisms. Front Cardiovasc Med. 2022;9:933215. doi: 10.3389/fcvm.2022.933215
Polyakova EA, Mikhaylov EN, Sonin DL, Cheburkin Y V, Galagudza MM. Neurohumoral, cardiac and inflammatory markers in the evaluation of heart failure severity and progression. J Geriatr Cardiol JGC. 2021;18(1):47. doi: 10.11909/j.issn.1671-5411.2021.01.007
Rahbar Kouibaran F, Sabatino M, Barozzi C, Diemberger I. Atrial natriuretic peptides as a bridge between atrial fibrillation, heart failure, and amyloidosis of the atria. Int J Mol Sci. 2023;24(7):6470. doi: 10.3390/ijms24076470
Novikova D, Kirillova I, Markelova E, et al. P4434The first report of significantly improvement of NT-proBNP level in rheumatoid arthritis patients treated with tofacitinib during 12-month follow-up. Eur Heart J. 2019;40(Supplement_1):ehz745.0836. doi:10.1093/eurheartj/ehz745.0836
O’Neill RS, Emmanuel S, Williams D, Stoita A. Macrophage inhibitory cytokine-1/growth differentiation factor-15 in premalignant and neoplastic tumours in a high-risk pancreatic cancer cohort. World J Gastroenterol. 2020;26(14):1660. doi: 10.3748/wjg.v26.i14.1660
Wischhusen J, Melero I, Fridman WH. Growth/differentiation factor-15 (GDF-15): from biomarker to novel targetable immune checkpoint. Front Immunol. 2020;11:951. doi: 10.3389/fimmu.2020.00951
Luo H. GDF15 in Doxorubicin Cardiotoxicity. 2022.
Brenière C, Méloux A, Pédard M, et al. Growth differentiation factor-15 (GDF-15) is associated with mortality in ischemic stroke patients treated with acute revascularization therapy. Front Neurol. 2019;10:611. doi: 10.3389/fneur.2019.00611
Jewad AM, Shwayel AJ. Evaluation of some nonroutine cardiac biomarkers among adults and children with beta-thalassemia major. Lab Med. 2024:lmae007. doi: 10.1093/labmed/lmae007
Fischer JP, Els-Heindl S, Beck-Sickinger AG. Adrenomedullin–current perspective on a peptide hormone with significant therapeutic potential. Peptides. 2020;131:170347. doi: 10.1016/j.peptides.2020.170347
Litmanovich A, Moady G, Saad M, Blumberg Y, Ertracht O, Qvit N. Cardiovascular-derived therapeutic peptidomimetics in cardiovascular disease. Peptide and Peptidomimetic Therapeutics. 2022:579-614. doi: 10.1016/B978-0-12-820141-1.00013-3
Kaufmann P, Ilina Y, Press M, Bergmann A. Sandwich immunoassay for adrenomedullin precursor and its practical application. Sci Rep. 2024;14(1):28091.doi: s41598-024-79542-5
Chiorescu RM, Lazar RD, Buksa SB, Mocan M, Blendea D. Biomarkers of volume overload and edema in heart failure with reduced ejection fraction. Front Cardiovasc Med. 2022;9:910100. doi: 10.3389/fcvm.2022.910100
Simonavičius J, Mikalauskas A, Čerlinskaitė K, et al. Biologically Active Adrenomedullin (bio-ADM) is of Potential Value in Identifying Congestion and Selecting Patients for Neurohormonal Blockade in Acute Dyspnea. Am J Med. 2022;135(7):e165-e181. doi: 10.1016/j.amjmed.2022.02.006
Radu AF, Bungau SG. Management of rheumatoid arthritis: an overview. Cells. 2021;10(11):2857. doi: 10.3390/cells10112857
Shapiro SC. Biomarkers in rheumatoid arthritis. Cureus. 2021;13(5):e15063. doi: 10.7759/cureus.15063
Fathy HM, Rafat S, Abd-ElAzeem MI, Abdou LM, Abd Elbaset AS, Tantawy M. CRP-Albumin Ratio as A Disease Activity Marker in RA Patients, Its Correlation with Musculoskeletal Sonography. Egypt J Hosp Med. 2023;92(1):5496-5502. doi: 10.21608/ejhm.2023.305791
Cooper J, Pastorello Y, Slevin M. A meta-analysis investigating the relationship between inflammation in autoimmune disease, elevated CRP, and the risk of dementia. Front Immunol. 2023;14:1087571. doi: 10.3389/fimmu.2023.1087571
Cuesta-López L, Escudero-Contreras A, Hanaee Y, et al. Exploring candidate biomarkers for rheumatoid arthritis through cardiovascular and cardiometabolic serum proteome profiling. Front Immunol. 2024;15:1333995. doi: 10.3389/fimmu.2024.1333995
Zhou J, Dai Y, Lin Y, Chen K. Association between serum amyloid A and rheumatoid arthritis: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2022;52:151943. doi: 10.1016/j.semarthrit.2021.12.011
Speelman T, Dale L, Louw A, Verhoog NJD. The association of acute phase proteins in stress and inflammation-induced T2D. Cells. 2022;11(14):2163.doi: 10.3390/cells11142163
Jrad AIS, Trad M, Bzeih W, El Hasbani G, Uthman I. Role of pro-inflammatory interleukins in osteoarthritis: a narrative review. Connect Tissue Res. 2023;64(3):238-247. doi: 10.1080/03008207.2022.2157270
Sorić Hosman I, Kos I, Lamot L. Serum Amyloid A in Inflammatory Rheumatic Diseases: A Compendious Review of a Renowned Biomarker. Front Immunol. 2021;11:631299. doi: 10.3389/fimmu.2020.631299
Fragoulis GE, Soulaidopoulos S, Sfikakis PP, Dimitroulas TD, Kitas G. Effect of biologics on cardiovascular inflammation: mechanistic insights and risk reduction. J Inflamm Res. 2021:1915-1931. doi: 10.2147/JIR.S282691
Mostafa TM, Hegazy SK, Elshebini EM, Saif DS, Elabd AH. A comparative study on the anti-inflammatory effect of angiotensin-receptor blockers & statins on rheumatoid arthritis disease activity. Indian J Med Res. 2020;152(4):393-400. doi: 10.4103/ijmr.IJMR_640_19
Lin K, Luo W, Yan J, et al. TLR2 regulates angiotensin II-induced vascular remodeling and EndMT through NF-κB signaling. Aging (Albany NY). 2020;13(2):2553. doi: 10.18632/aging.202290
Satou R, Franco M, Dugas CM, Katsurada A, Navar LG. Immunosuppression by mycophenolate mofetil mitigates intrarenal angiotensinogen augmentation in angiotensin II-dependent hypertension. Int J Mol Sci. 2022;23(14):7680. doi: 10.3390/ijms23147680
Wang F, So KF, Xiao J, Wang H. Organ-organ communication: The liver’s perspective. Theranostics. 2021;11(7):3317. https://doi: 10.7150/thno.55795
Ferreira MB, Fonseca T, Costa R, et al. Prevalence, risk factors and proteomic bioprofiles associated with heart failure in rheumatoid arthritis: The RA-HF study. Eur J Intern Med. 2021;85:41-49. doi: 10.1016/j.ejim.2020.11.002
Hu G, Peng X, He L, et al. Pro‐adrenomedullin as an independent predictive biomarker for heart failure in atrial fibrillation and flutter. ESC Hear Fail. 2025. doi: 10.1002/ehf2.15196
Wang X, Fan D, Cao X, et al. The role of reactive oxygen species in the rheumatoid arthritis-associated synovial microenvironment. Antioxidants. 2022;11(6):1153. doi: 10.3390/antiox11061153
Mahmoodazdeh A, Shafiee SM, Sisakht M, Khoshdel Z, Takhshid MA. Adrenomedullin protects rat dorsal root ganglion neurons against doxorubicin-induced toxicity by ameliorating oxidative stress. Iran J Basic Med Sci. 2020;23(9):1197. doi: 10.22038/ijbms.2020.45134.10514
Garduno A, Cusack R, Leone M, Einav S, Martin-Loeches I. Multi-omics endotypes in ICU sepsis-induced immunosuppression. Microorganisms. 2023;11(5):1119. doi: 10.3390/microorganisms11051119
Ye L, Zuo Y, Chen F, et al. Adrenomedullin expression is associated with the severity and poor prognosis of interstitial lung disease in dermatomyositis patients. Front Immunol. 2022;13:885142. doi: 10.3389/fimmu.2022.885142
Sacco MA, Gualtieri S, Cordasco F, et al. The Role of Adrenomedullin as a Predictive Marker of the Risk of Death and Adverse Clinical Events: A Review of the Literature. J Clin Med. 2024;13(16):4847. doi: 10.3390/jcm13164847
Arnold N, Rehm M, Büchele G, et al. Growth differentiation factor-15 as a potent predictor of long-term mortality among subjects with osteoarthritis. J Clin Med. 2020;9(10):3107. doi: 10.3390/jcm9103107
di Candia AM, de Avila DX, Moreira GR, Villacorta H, Maisel AS. Growth differentiation factor-15, a novel systemic biomarker of oxidative stress, inflammation, and cellular aging: Potential role in cardiovascular diseases. Am Hear J Plus Cardiol Res Pract. 2021;9:100046. doi: 10.1016/j.ahjo.2021.100046
Abdulridha GAO, Hussein MA, Majeed SR. High Growth Differentiation Factor-15 (GDF-15) in Rheumatoid Arthritis Patients Potential Risk for Cardiovascular Disease. J Angiother. 2024;8(3):1-8. doi: 10.25163/angiotherapy.839595
Hofstedt O, Wahlin B, Södergren A. Associations between serological biomarkers and subclinical atherosclerosis in patients with rheumatoid arthritis after 11 years of follow-up. Clin Exp Rheumatol. 2024;42(5):967-973. doi:10.55563/clinexprheumatol/70qiy8
Tanrıkulu O, Sarıyıldız MA, Batmaz İ, et al. Serum GDF-15 level in rheumatoid arthritis: relationship with disease activity and subclinical atherosclerosis. Acta Reumatol Port. 2017;(1).doi:ncbi.nlm.nih.gov/27679935/
Gangnus T, Burckhardt BB. Potential and limitations of atrial natriuretic peptide as biomarker in pediatric heart failure-a comparative review. Front Pediatr. 2019;6:420. doi: 10.3389/fped.2018.00420
Ankudinov AS. Association of pentrakisn-3 and atrial natriuretic peptide in patients with chronic heart failure and rheumatoid arthritis. Atherosclerosis. 2021;331:e268. doi: 10.1016/j.atherosclerosis.2021.06.822
da Silva GJJ, Altara R, Booz GW, Cataliotti A. Atrial natriuretic peptide31-67: a novel therapeutic factor for cardiovascular diseases. Front Physiol. 2021;12:691407. doi: 10.3389/fphys.2021.691407
Raud B, Gay C, Guiguet-Auclair C, et al. Level of obesity is directly associated with the clinical and functional consequences of knee osteoarthritis. Sci Rep. 2020;10(1):3601.doi: s41598-020-60587-1
Dubiel-Braszczok B, Nowak K, Owczarek A, Engelmann M, Gumkowska-Sroka O, Kotyla PJ. Differential Impact of Biologic Therapy on Heart Function Biomarkers in Rheumatoid Arthritis Patients: Observational Study on Etanercept, Adalimumab, and Tocilizumab. Curr Pharm Des. 2022;28(24):2029-2037. doi: 10.2174/1381612828666220527141532
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 European Journal of Clinical and Experimental Medicine
This work is licensed under a Creative Commons Attribution 4.0 International License.
Our open access policy is in accordance with the Budapest Open Access Initiative (BOAI) definition: this means that articles have free availability on the public Internet, permitting any users to read, download, copy, distribute, print, search, or link to the full texts of these articles, crawl them for indexing, pass them as data to software, or use them for any other lawful purpose, without financial, legal, or technical barriers other than those inseparable from having access to the Internet itself.
All articles are published with free open access under the CC-BY Creative Commons attribution license (the current version is CC-BY, version 4.0). If you submit your paper for publication by the Eur J Clin Exp Med, you agree to have the CC-BY license applied to your work. Under this Open Access license, you, as the author, agree that anyone may download and read the paper for free. In addition, the article may be reused and quoted provided that the original published version is cited. This facilitates freedom in re-use and also ensures that Eur J Clin Exp Med content can be mined without barriers for the research needs.
